Tu K L, Palimar P, Sen S, Mathew P, Khaleeli A
Department of Opthalmology, Warrington Hospital, Warrington, UK.
Eye (Lond). 2004 Jan;18(1):3-8. doi: 10.1038/sj.eye.6700497.
To compare (a). the clinical effectiveness and (b). cost effectiveness of the two models in screening for diabetic retinopathy.
(a). Retrospective analysis of referral diagnoses of each screening model in their first respective years of operation and an audit of screen positive patients and a sample of screen negatives referred to the hospital eye service from both screening programmes. (b). Cost effectiveness study.
(1). A total of 1643 patients screened in the community and in digital photography clinics; (2). 109 consecutive patients referred to the Diabetic Eye Clinic through the two existing models of diabetic retinopathy screening; (3). 55 screen negative patients from the optometry model; (4). 68 screen negative patients audited from the digital photography model.
The compliance rate was 45% for optometry (O) vs 50% for the digital imaging system (I). Background retinopathy was recorded at screening in 22% (O) vs 17% (I) (P=0.03) and maculopathy in 3.8% (O) vs 1.7% (I) (P=0.02). Hospital referral rates were 3.8% (O) vs 4.2% (I) Sensitivity (75% for optometry, 80% for digital photography) and specificity (98% for optometry and digital photography) were similar in both models. The cost of screening each patient was pound 23.99 (O) vs pound 29.29 (I). The cost effectiveness was pound 832 (O) vs pound 853(I) in the first year.
The imaging system was not always able to detect early retinopathy and maculopathy; it was equally specific in identifying sight-threatening disease. Cost effectiveness was poor in both models, in their first operational year largely as a result of poor compliance rates in the newly introduced screening programme. Cost effectiveness of the imaging model should further improve with falling costs of imaging systems. Until then, it is essential to continue any existing well-coordinated optometry model.
比较(a)两种模式在糖尿病视网膜病变筛查中的临床有效性和(b)成本效益。
(a)对每个筛查模式各自运营的第一年的转诊诊断进行回顾性分析,并对筛查呈阳性的患者以及从两个筛查项目转诊至医院眼科服务的一部分筛查呈阴性的患者进行审核。(b)成本效益研究。
(1)共有1643名在社区和数码摄影诊所接受筛查的患者;(2)通过两种现有的糖尿病视网膜病变筛查模式转诊至糖尿病眼科诊所的109名连续患者;(3)验光模式下的55名筛查呈阴性的患者;(4)从数码摄影模式审核的68名筛查呈阴性的患者。
验光(O)的依从率为45%,而数码成像系统(I)的依从率为50%。筛查时记录的背景性视网膜病变在验光组为22%,在数码成像系统组为17%(P = 0.03),黄斑病变在验光组为3.8%,在数码成像系统组为1.7%(P = 0.02)。医院转诊率在验光组为3.8%,在数码成像系统组为4.2%。两种模式的敏感性(验光为75%,数码摄影为80%)和特异性(验光和数码摄影均为98%)相似。筛查每名患者的成本在验光组为23.99英镑,在数码成像系统组为29.29英镑。第一年的成本效益在验光组为832英镑,在数码成像系统组为853英镑。
成像系统并非总能检测出早期视网膜病变和黄斑病变;在识别威胁视力的疾病方面具有同等的特异性。两种模式在其运营的第一年成本效益都很差,这主要是由于新引入的筛查项目依从率低所致。随着成像系统成本的下降,成像模式的成本效益应会进一步提高。在此之前,继续现有的任何协调良好的验光模式至关重要。